CompanyHealthHardware
Lycia Therapeutics
Lycia Therapeutics is a South San Francisco biotech building lysosomal targeting chimeras (LYTACs) - bifunctional molecules that drag disease-driving extracellular and membrane proteins into the cell's lysosomes for destruction. Founded in 2019 out of the lab of Nobel laureate Carolyn Bertozzi, Lycia is advancing a pipeline of autoimmune and inflammatory disease therapies, backed by $226M+ in venture capital and a strategic discovery collaboration with Eli Lilly.
2019Founded
South San FranciscoHQ
$106.6MSeries C
biotechlytacprotein-degradationautoimmunedrug-discoverylysosomal-targeting